TA01 是一种心源性抑制剂，有效抑制CK1和p38 MAPK，其对 CK1ε，CK1δ 和 p38 MAPK 的IC50值分别为 6.4 nM，6.8 nM 和 6.7 nM。

TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.

TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 (5 μM) is not cytotoxic, completely inhibits cardiogenesis, but induces cardiogenesis at lower concentration[1].

Compounds (TA-01) are dissolved in DMSO?and tested at?10 μM concentrations?against a panel of 97 kinases, which are related to stem cell differentiation and cell signaling pathways. Kinome profiling is carried out by kinase profiling service[1].

HES-3, H7 and IPS are harvested and seeded at 1.1 × 106 cells/mL as EBs in ultra-low attachment 12-well plates in bSFS medium: DMEM supplemented with 2 mM l-glutamine, 0.182 mM sodium pyruvate, 1% non-essential amino acids, 0.1 mM β-mercaptoethanol, 5.6 mg/L transferrin, 20 μg/L sodium selenite, 0.25% (w/vol) Bovine Serum Albumin and 0.25% (w/vol) Hysoy. Cells are incubated at 37°C and 5% CO2 to allow EB formation. The medium is refreshed after 1 day and then every 2-3 days. Cells are stimulated with the respective compounds (TA-01) dissolved in DMSO (1 μL DMSO/mL of media) starting from day 1 or day 4, until day 8. CHIR99021 is applied for the first 24 h only[1].

1784751-18-3

C20H12F3N3

351.332

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years